Subklinik hipotroidi hasta serumlarında homosistein ve irisin seviyelerinin tanısal öneminin belirlenmesi
Öz
Anahtar Kelimeler
Kaynakça
- 1. Cojić M, Cvejanov-Kezunović L. Subclinical Hypothyroidism – Whether and When To Start Treatment. Maced J Med Sci. 2017; 15; 5: 1042-6. 2. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98: E769-78. 3. Ateş İ, Altay M, Topçuoğlu C, Yılmaz FM. Circulating levels of irisin is elevated in hypothyroidism, a case-control study. Arch Endocrinol Metab. 2016; 60: 95-100. 4. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol. 2016; 67: 476-80. 5. Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J Pharmacol Sci 2014; 125: 125e131. 6. Hofmann T, Elbelt U, Stengel A. Irisin as a muscle-derived hormone stimulating thermogenesisea critical update. Peptides 2014; 54: 89e100. 7. Moreno M, Moreno-Navarrete JM, Serrano M, et al. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PLoS One. 2015; 10: e0124100. 8. Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014; 63: 1265-71. 9. Kuloglu T, Aydin S, Eren MN, et al. Irisin: a potentially candidate marker for myocardial infarction. Peptides. 2014; 55C: 85–91. 10. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis. 2001; 155: 195–200. 11. Bamashmoos SA, Al-Nuzaily MA, Al-Meeri AM, Ali FH. Relationship between total homocysteine, total cholesterol and creatinine levels in overt hypothyroid patients. Springerplus. 2013; 30: 423. Altay D.U., Ozdemır O., Noyan T., Yuksel S., Ayhan B.S. 756 12. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med 2009; 60: 39–54. 13. Selmer C, Olesen JB, Hansen ML,et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99: 2372–82. 14. Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97: 852–61. 15. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126: 1040–9. 16. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid Dysfunction and Heart Failure: Mechanisms and Associations. Curr Heart Fail Rep. 2017; 14: 48–58. 17. McAninch EA, Bianco AC. Thyroid hormone signaling in energy homeostasis and energy metabolism. Ann N Y Acad Sci. 2014; 1311: 77–87. 18. Zarković M. The deficit of thyroid hormones - effect on cardiovascular and cognitive functions. (srb. Deficit tiroidnih hormona – uticaj na kardiovaskularne i kognitivne funkcije.) Medical Gazette Special hospital for thyroid gland diseases and metabolic diseases Zlatibor (srb. Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor). 2007; 12: 47-53. 19. Klein I, Ojamaa K. Thyroid hormone and cardiovascular System. N Engl J Med. 2001; 344: 501-9. 20. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol. 2010; 52: 151–6. 21. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003; 88: 2438–44. 22. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I.Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab Clin Exp 2012; 61: 1725–38. 23. Samy DM, Ismail CA, Nassra RA. Circulating irisin concentrations in rat models of thyroid dysfunction – effect of exercise. Metabolism 2015; 64: 804–13. 24. Ruchala M, Zybek A, Szczepanek-Parulska E. Serum irisin levels and thyroid function – Newly discovered association. Peptides. 2014; 60: 51-5. 25. Yalcin MM, Akturk M, Tohma Y, et al. Irisin and myostatin levels in patients with Graves' disease. Arch Med Res 2016; 47: 471-5. 26. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol 2016; 67: 476-80 27. Ellefsen S, Vikmoen O, Slettaløkken G, et al. Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women. Eur J Appl Physiol 2014: 114; 1875–88. 28. Stengel A, Hofmann T, Goebel-Stengel M, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – correlation with body mass index. Peptides 2013; 39: 125–30.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yazarlar
Diler Us Altay
0000-0002-0465-8403
Türkiye
Ozlem Ozdemır
Bu kişi benim
0000-0001-5088-4316
Türkiye
Tevfik Noyan
Bu kişi benim
0000-0002-7733-0177
Türkiye
Sefa Yuksel
Bu kişi benim
0000-0002-5863-1775
Türkiye
Burhanettin Sertaç Ayhan
Bu kişi benim
0000-0002-1915-1306
Türkiye
Yayımlanma Tarihi
15 Aralık 2019
Gönderilme Tarihi
27 Haziran 2019
Kabul Tarihi
6 Kasım 2019
Yayımlandığı Sayı
Yıl 2019 Cilt: 46 Sayı: 4